In 2024, Samsung Biologics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Samsung Biologics has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 71,971.718a | 69,262.496a | 54,575.447a | |
Total Scope 2 | ||||
Market-Based | 115,827.854a | 113,313a | 99,918a | |
Location-Based | 161,737.351a | 150,436.067a | 109,423.754a | |
Unspecified Calculation Method | N/A | N/A | N/A | |
Total Scope 3 | 448,410.157a | 513,803a | 791,712.059a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 23.2248a | 23.9557a | 22.9165a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Samsung Biologics amounted to 233,709.069 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Samsung Biologics increased by 6.38%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Samsung Biologics were 71,971.718 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Samsung Biologics's Scope 1 emissions have increased by 73.56%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Samsung Biologics's Scope 1 emissions increased by 3.91%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Samsung Biologics reported Scope 2 greenhouse gas (GHG) emissions of 115,827.854 tCO₂e using the market-based method and 161,737.351 tCO₂e using the location-based method.a
Compared to the previous year (2023), Samsung Biologics's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Samsung Biologics's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Samsung Biologics reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Samsung Biologics reported 448,410.157 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Samsung Biologics includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Samsung Biologics reported total Scope 3 emissions of 448,410.157 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 91.89% of these emissions originated from upstream activities such as purchased goods and capital goods, while 8.11% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Samsung Biologics's Scope 3 emissions decreased by 12.73%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2024, Samsung Biologics reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Samsung Biologics's Scope 3 emissions were:a
In 2024, Samsung Biologics reported Scope 1 greenhouse gas (GHG) emissions of 71,971.718 tCO₂e and total revenues of USD 3,099 millions. This translates into an emissions intensity of 23.22 tCO₂e per millions USD.a
In 2024, Samsung Biologics reported a Scope 1 emissions intensity of 23.22 tCO₂e per millions USD. Compared to the peer group median of 4.12, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Samsung Biologics ranked 24 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Samsung Biologics among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2024, Samsung Biologics reported a total carbon footprint of 682,119.226 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 7.01% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Samsung Biologics's total carbon footprint was Scope 3 emissions, accounting for 65.74% of the company's total carbon footprint, followed by Scope 2 emissions at 23.71%.a